Argeris Karabelas will become the new chairman of the board of directors of Human Genome Sciences next month, replacing William Haseltime after his retirement, the company said on Monday. Karabelas is a partner of investment firm Care Capital and has been a director of Human Genome Sciences since 2002. He holds a PhD in pharmacokinetics from the Massachusetts College of Pharmacy. In addition, Human Genome Sciences has promoted Craig Rosen to president and chief operating officer, from president for research and development. Laura D’Andrea Tyson will retire from the company’s board of directors.
Argeris Karabelas, William Haseltime, Laura D Andrea Tyson
Sep 23, 2004